Safety and effectiveness of transdermal buprenorphine in cancer pain: An observational study in Taiwan (SOOTHE). Issue 2 (22nd May 2022)

• Record Type: Journal Article
• Authors: Huang, Tai‐Lin; Huang, Yen‐Min; Hou, Min‐Mo; Lu, Chang‐Hsien; Chao, Tsu‐Yi; Chiu, Tai‐Jan; Chang, Yueh‐Shih; Lin, Sheng‐Hao; Lin, Ching‐Hsiung; Chen, Yen‐Hao; Wang, Cheng‐Hsu; Chen, Jen‐Shi; Shen, Wen‐Chi
• Is Part Of: Asia-Pacific journal of clinical oncology. Volume 19:Issue 2(2023)
• Page Start: e45
• Page End: e53
• Publication Date: 2022-05-22
• Subjects: anxiety/depression -- cancer pain -- pain control -- transdermal buprenorphine; Oncology -- Pacific Area -- Periodicals; Cancer -- Treatment -- Pacific Area -- Periodicals; Cancer -- Pacific Area -- Periodicals; Cancer -- Treatment -- Periodicals; 616.9940095
• DOI: 10.1111/ajco.13772
• Languages: English
• ISSNs: 1743-7555

Abstract

Abstract: Aim: Buprenorphine is one of the strongest opioids used for the relief of cancer pain. This study aims to evaluate the real‐world clinical experiences of transdermal buprenorphine used in moderate to severe cancer pain in the Asian population. Methods: This is an open‐labeled, multicenter, 4‐week observational study. Stable cancer pain patients who decided to switch the previous opioid to transdermal buprenorphine will be enrolled in this study. The safety and effectiveness were observed and collected. Pain assessment was performed using a numerical rating scale by the investigators and the Brief Pain Inventory Short Form (BPI‐SF) by the patient. The safety profiles included concomitant medications and adverse events (AEs). Results: A total of 83 patients were enrolled in this study. The global pain scores in the BPI, as well as the four individual pain parameters (worst, least, average, and right now), showed a continued decrease ( p < .05) from week 2 to week 4. Significant improvements were observed in normal work activities, relations with other people, sleep, enjoyment of life, and global BPI pain interference score on week 4. Pain assessments conducted by investigators demonstrated significant, continuous improvements during the study periods. In addition, transdermal buprenorphine demonstrated good safety/tolerability with limited drug‐related AEs in the Asian population with cancer pain. Conclusion: This study demonstrated that transdermal buprenorphine in the Asian population has good safety profiles and continued improvements in pain relief, sleep, and pain interferences. Transdermal buprenorphine can be an effective and convenient option as a transdermal opioid for patients with moderate to severe cancer pain in Taiwan. (NCT Number: NCT04315831) Abstract :